MEDI9090

MEDI9090 is an investigational antineoplastic drug developed for the treatment of advanced solid tumors. It was originally developed by MedImmune and later by AstraZeneca. The drug has been studied in a Phase 1 clinical trial to evaluate its safety, tolerability, pharmacokinetics (PK), immunogenicity, and antitumor activity in adult patients with advanced solid tumors. In this study, participants received fixed doses of durvalumab and tremelimumab alongside MEDI9090 as part of the treatment regimen. The precise mechanism of action for MEDI9090 has not been publicly disclosed[1][2][3][4]. As of the latest available information (2022), development appears to have remained at the Phase 1 stage without further reported progress[2].